Acute ischemic stroke (AIS) is a leading cause of morbidity and mortality globally. Standard antiplatelet therapies, while partially effective, do not fully inhibit all pathways of platelet aggregation, leaving patients… Click to show full abstract
Acute ischemic stroke (AIS) is a leading cause of morbidity and mortality globally. Standard antiplatelet therapies, while partially effective, do not fully inhibit all pathways of platelet aggregation, leaving patients at risk of recurrent thrombotic events. Tirofiban, a glycoprotein IIb/IIIa receptor inhibitor, has shown promise as an adjunctive treatment in AIS.
Keywords:
therapy acute;
acute ischemic;
combination therapy;
ischemic stroke;
tirofiban combination
Journal Title: Brain and Behavior
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Brain and Behavior
Year Published: 2025
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!